Ask
Search
My library
ORKG

ORKG Ask

Our mission is to organize scholarly knowledge and make it accessible to humans and machines.

About

About ORKG Ask
Report issue
Statistics
Contact

Legal

Terms of use
Data protection (sheet)
Imprint
Accessibility
License

Technical

We
open source
System status
Changelog
Frontend: v1.41.0
Backend: v1.13.4

We use cookies to provide a better user experience.

Data Protection

Number of participants that discontinued regimens or missed quality of life assessment.

Shashi N. Kapadia (6157124)
Chunyuan Wu (346681)
Kenneth H. Mayer (116219)
Timothy J. Wilkin (559933)
K. Rivet Amico (499213)
Raphael J. Landovitz (5945888)
Adriana Andrade (499188)
Ying Q. Chen (3911827)
Wairimu Chege (6157127)
Marybeth McCauley (3911830)
Roy M. Gulick (263605)
Bruce R. Schackman (343666)

Publication date

December 2018

DOI

10.1371/journal.pone.0206577.t002

Publisher

Public Library of Science (PLoS)

Abstract

Number of participants that discontinued regimens or missed quality of life assessment.</p

Extracted data

Related items

Number of subjects included and excluded for baseline and 4-year follow-up analyses.

Ruth Chan (254624)
Dicken Chan (620182)
Jean Woo (240342)

August 2014

<p>Number of subjects included and excluded for baseline and 4-year follow-up analyses.</p

Prevalence of quitting behaviors and cessation stages among all participants (N = 3,929).

Wonjeong Yoon (6645704)
Inhyung Cho (13767368)
Sung-il Cho (231795)

September 2022

Prevalence of quitting behaviors and cessation stages among all participants (N = 3,929).</p

Data on participation and missing at follow-up for traditional and alternative interventions.

Federico Roncarolo (3180069)
Sherri Bisset (578419)
Louise Potvin (62249)

March 2016

<p>Data on participation and missing at follow-up for traditional and alternative interventions.</p

Showing the number of patients discontinuing therapy and the primary documented causes by drug group.

Michael Scolarici (5979566)
Ken Dekitani (5979569)
Ling Chen (25698)
Marcia Sokol-Anderson (5979572)
Daniel F. Hoft (104230)
Soumya Chatterjee (473957)

November 2018

Showing the number of patients discontinuing therapy and the primary documented causes by drug group...

Number of participants, missing data, fully completed questionnaires, and included questionnaires.

Hannes Schröter (2806963)
Beatrix Studzinski (2806960)
Pavel Dietz (484147)
Rolf Ulrich (484148)
Heiko Striegel (484150)
Perikles Simon (363393)

May 2016

<p>Number of participants, missing data, fully completed questionnaires, and included questionnaires...

Numbers of medications initiated for each indication and discontinued within observation period by indication and medication type.

William King (3013917)
Arron Lacey (3841672)
James White (359733)
Daniel Farewell (3822376)
Frank Dunstan (18252)
David Fone (3543758)

March 2018

<p>Numbers of medications initiated for each indication and discontinued within observation period b...

Proportion of patients discontinuing from the AmoCongo ART program over time.

Olivier Koole (68979)
Lucien Kalenga (315708)
Modeste Kiumbu (315710)
Joris Menten (95438)
Robert W. Ryder (315712)
Henri Mukumbi (199615)
Robert Colebunders (10697)

February 2013

<p>Proportion of patients discontinuing from the AmoCongo ART program over time.</p

Number of therapist questionnaires and patient observation sessions completed.

Gavin Williams (1389984)
Linda Denehy (37646)

February 2019

Number of therapist questionnaires and patient observation sessions completed.</p

Number of participants and number of deceased persons during the study period.

Corinna Vossius (595382)
Geir Selbæk (518247)
Jurate Šaltytė Benth (5759237)
Sverre Bergh (5738261)

September 2018

Number of participants and number of deceased persons during the study period.</p

Rate of discontinuations due to adverse events.

Karin Neukam (584773)
Daniela I. Munteanu (731760)
Antonio Rivero-Juárez (299565)
Thomas Lutz (420561)
Jan Fehr (174310)
Mattias Mandorfer (584776)
Sanjay Bhagani (300128)
Luis F. López-Cortés (189634)
Annette Haberl (731761)
Marcel Stoeckle (731762)
Manuel Márquez (731763)
Stefan Scholten (210941)
Ignacio de los Santos-Gil (731764)
Stefan Mauss (143062)
Antonio Rivero (189661)
Antonio Collado (464581)
Marcial Delgado (731765)
Juergen K. Rockstroh (731766)
Juan A. Pineda (189667)

April 2015

<p>Proportion of patients who permanently discontinued all therapy due to adverse events after strat...

Change in quality of life measures from baseline to end of follow-up by comorbidity count.

Elaine W. Butterly (11306428)
Peter Hanlon (3498404)
Anoop S. V. Shah (10532441)
Laurie J. Hannigan (8834189)
Emma McIntosh (787413)
Jim Lewsey (9548349)
Sarah H. Wild (7512197)
Bruce Guthrie (434189)
Frances S. Mair (7784447)
David M. Kent (8637552)
Sofia Dias (498430)
Nicky J. Welton (7258427)
David A. McAllister (9548352)

January 2023

Change in quality of life measures from baseline to end of follow-up by comorbidity count.</p

Comparisons of demographics among participants discontinued anti-osteoporosis medication due to different causes.

Ya-Lian Deng (13840348)
Chun-Sheng Hsu (13840351)
Chiann-Yi Hsu (4722339)
Chih-Hui Chen (3864247)
Shiang-Ferng Ou (13840354)
Chin-Feng Liu (13840357)
Shu-Hui Yang (3616451)
Chun-Hsi Shih (13840360)
Yi-Ming Chen (511275)
Hsu-Tung Lee (365699)

September 2022

Comparisons of demographics among participants discontinued anti-osteoporosis medication due to diff...

Proportion of patients discontinuing from the AmoCongo ART program at 1 year by the 6 study sites.

Olivier Koole (68979)
Lucien Kalenga (315708)
Modeste Kiumbu (315710)
Joris Menten (95438)
Robert W. Ryder (315712)
Henri Mukumbi (199615)
Robert Colebunders (10697)

February 2013

<p>Proportion of patients discontinuing from the AmoCongo ART program at 1 year by the 6 study sites...

Number of patients showing any impairment on neuropsychological assessments.

Zainab Samaan (516751)
Stephanie McDermid Vaz (3163095)
Monica Bawor (516749)
Tammy Hlywka Potter (3163092)
Sasha Eskandarian (3163098)
Mark Loeb (248712)

June 2016

<p>Number of patients showing any impairment on neuropsychological assessments.</p

Proportion/Number of participants in each trajectory group and cognitive status at end of follow-up.

Xiuhua Ding (657355)
Richard J. Charnigo (5363087)
Frederick A. Schmitt (6397586)
Richard J. Kryscio (807132)
Erin L. Abner (848340)

February 2019

Proportion/Number of participants in each trajectory group and cognitive status at end of follow-up....

Number of subjects included and excluded for baseline and 4-year follow-up analyses.

Ruth Chan (254624)
Dicken Chan (620182)
Jean Woo (240342)

August 2014

<p>Number of subjects included and excluded for baseline and 4-year follow-up analyses.</p

Prevalence of quitting behaviors and cessation stages among all participants (N = 3,929).

Wonjeong Yoon (6645704)
Inhyung Cho (13767368)
Sung-il Cho (231795)

September 2022

Prevalence of quitting behaviors and cessation stages among all participants (N = 3,929).</p

Data on participation and missing at follow-up for traditional and alternative interventions.

Federico Roncarolo (3180069)
Sherri Bisset (578419)
Louise Potvin (62249)

March 2016

<p>Data on participation and missing at follow-up for traditional and alternative interventions.</p

Showing the number of patients discontinuing therapy and the primary documented causes by drug group.

Michael Scolarici (5979566)
Ken Dekitani (5979569)
Ling Chen (25698)
Marcia Sokol-Anderson (5979572)
Daniel F. Hoft (104230)
Soumya Chatterjee (473957)

November 2018

Showing the number of patients discontinuing therapy and the primary documented causes by drug group...

Number of participants, missing data, fully completed questionnaires, and included questionnaires.

Hannes Schröter (2806963)
Beatrix Studzinski (2806960)
Pavel Dietz (484147)
Rolf Ulrich (484148)
Heiko Striegel (484150)
Perikles Simon (363393)

May 2016

<p>Number of participants, missing data, fully completed questionnaires, and included questionnaires...

Numbers of medications initiated for each indication and discontinued within observation period by indication and medication type.

William King (3013917)
Arron Lacey (3841672)
James White (359733)
Daniel Farewell (3822376)
Frank Dunstan (18252)
David Fone (3543758)

March 2018

<p>Numbers of medications initiated for each indication and discontinued within observation period b...

Proportion of patients discontinuing from the AmoCongo ART program over time.

Olivier Koole (68979)
Lucien Kalenga (315708)
Modeste Kiumbu (315710)
Joris Menten (95438)
Robert W. Ryder (315712)
Henri Mukumbi (199615)
Robert Colebunders (10697)

February 2013

<p>Proportion of patients discontinuing from the AmoCongo ART program over time.</p

Number of therapist questionnaires and patient observation sessions completed.

Gavin Williams (1389984)
Linda Denehy (37646)

February 2019

Number of therapist questionnaires and patient observation sessions completed.</p

Number of participants and number of deceased persons during the study period.

Corinna Vossius (595382)
Geir Selbæk (518247)
Jurate Šaltytė Benth (5759237)
Sverre Bergh (5738261)

September 2018

Number of participants and number of deceased persons during the study period.</p

Rate of discontinuations due to adverse events.

Karin Neukam (584773)
Daniela I. Munteanu (731760)
Antonio Rivero-Juárez (299565)
Thomas Lutz (420561)
Jan Fehr (174310)
Mattias Mandorfer (584776)
Sanjay Bhagani (300128)
Luis F. López-Cortés (189634)
Annette Haberl (731761)
Marcel Stoeckle (731762)
Manuel Márquez (731763)
Stefan Scholten (210941)
Ignacio de los Santos-Gil (731764)
Stefan Mauss (143062)
Antonio Rivero (189661)
Antonio Collado (464581)
Marcial Delgado (731765)
Juergen K. Rockstroh (731766)
Juan A. Pineda (189667)

April 2015

<p>Proportion of patients who permanently discontinued all therapy due to adverse events after strat...

Change in quality of life measures from baseline to end of follow-up by comorbidity count.

Elaine W. Butterly (11306428)
Peter Hanlon (3498404)
Anoop S. V. Shah (10532441)
Laurie J. Hannigan (8834189)
Emma McIntosh (787413)
Jim Lewsey (9548349)
Sarah H. Wild (7512197)
Bruce Guthrie (434189)
Frances S. Mair (7784447)
David M. Kent (8637552)
Sofia Dias (498430)
Nicky J. Welton (7258427)
David A. McAllister (9548352)

January 2023

Change in quality of life measures from baseline to end of follow-up by comorbidity count.</p

Comparisons of demographics among participants discontinued anti-osteoporosis medication due to different causes.

Ya-Lian Deng (13840348)
Chun-Sheng Hsu (13840351)
Chiann-Yi Hsu (4722339)
Chih-Hui Chen (3864247)
Shiang-Ferng Ou (13840354)
Chin-Feng Liu (13840357)
Shu-Hui Yang (3616451)
Chun-Hsi Shih (13840360)
Yi-Ming Chen (511275)
Hsu-Tung Lee (365699)

September 2022

Comparisons of demographics among participants discontinued anti-osteoporosis medication due to diff...

Proportion of patients discontinuing from the AmoCongo ART program at 1 year by the 6 study sites.

Olivier Koole (68979)
Lucien Kalenga (315708)
Modeste Kiumbu (315710)
Joris Menten (95438)
Robert W. Ryder (315712)
Henri Mukumbi (199615)
Robert Colebunders (10697)

February 2013

<p>Proportion of patients discontinuing from the AmoCongo ART program at 1 year by the 6 study sites...

Number of patients showing any impairment on neuropsychological assessments.

Zainab Samaan (516751)
Stephanie McDermid Vaz (3163095)
Monica Bawor (516749)
Tammy Hlywka Potter (3163092)
Sasha Eskandarian (3163098)
Mark Loeb (248712)

June 2016

<p>Number of patients showing any impairment on neuropsychological assessments.</p

Proportion/Number of participants in each trajectory group and cognitive status at end of follow-up.

Xiuhua Ding (657355)
Richard J. Charnigo (5363087)
Frederick A. Schmitt (6397586)
Richard J. Kryscio (807132)
Erin L. Abner (848340)

February 2019

Proportion/Number of participants in each trajectory group and cognitive status at end of follow-up....

Number of subjects included and excluded for baseline and 4-year follow-up analyses.

Ruth Chan (254624)
Dicken Chan (620182)
Jean Woo (240342)

August 2014

<p>Number of subjects included and excluded for baseline and 4-year follow-up analyses.</p

Prevalence of quitting behaviors and cessation stages among all participants (N = 3,929).

Wonjeong Yoon (6645704)
Inhyung Cho (13767368)
Sung-il Cho (231795)

September 2022

Prevalence of quitting behaviors and cessation stages among all participants (N = 3,929).</p

Data on participation and missing at follow-up for traditional and alternative interventions.

Federico Roncarolo (3180069)
Sherri Bisset (578419)
Louise Potvin (62249)

March 2016

<p>Data on participation and missing at follow-up for traditional and alternative interventions.</p